BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

372 related articles for article (PubMed ID: 28088573)

  • 21. Heat shock protein antagonists in early stage clinical trials for NSCLC.
    Hendriks LEL; Dingemans AC
    Expert Opin Investig Drugs; 2017 May; 26(5):541-550. PubMed ID: 28274158
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The promise of heat shock protein inhibitors in the treatment of castration resistant prostate cancer.
    Ischia J; Saad F; Gleave M
    Curr Opin Urol; 2013 May; 23(3):194-200. PubMed ID: 23385973
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Heat shock proteins as emerging therapeutic targets.
    Sõti C; Nagy E; Giricz Z; Vígh L; Csermely P; Ferdinandy P
    Br J Pharmacol; 2005 Nov; 146(6):769-80. PubMed ID: 16170327
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeting hsp90 family members: A strategy to improve cancer cell death.
    Buc Calderon P; Beck R; Glorieux C
    Biochem Pharmacol; 2019 Jun; 164():177-187. PubMed ID: 30981878
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Heat shock proteins in cancer: targeting the 'chaperones'.
    Nahleh Z; Tfayli A; Najm A; El Sayed A; Nahle Z
    Future Med Chem; 2012 May; 4(7):927-35. PubMed ID: 22571616
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Heat shock protein 90: the cancer chaperone.
    Neckers L
    J Biosci; 2007 Apr; 32(3):517-30. PubMed ID: 17536171
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Role of integrated cancer nanomedicine in overcoming drug resistance.
    Iyer AK; Singh A; Ganta S; Amiji MM
    Adv Drug Deliv Rev; 2013 Nov; 65(13-14):1784-802. PubMed ID: 23880506
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Heat-shock protein 90 inhibitors as antitumor agents: a survey of the literature from 2005 to 2010.
    Messaoudi S; Peyrat JF; Brion JD; Alami M
    Expert Opin Ther Pat; 2011 Oct; 21(10):1501-42. PubMed ID: 21689065
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeted delivery of HSP90 inhibitors for efficient therapy of CD44-positive acute myeloid leukemia and solid tumor-colon cancer.
    Jia L; Yang H; Liu Y; Zhou Y; Li G; Zhou Q; Xu Y; Huang Z; Ye F; Ye J; Liu A; Ji C
    J Nanobiotechnology; 2024 Apr; 22(1):198. PubMed ID: 38649957
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Emerging Roles of Extracellular Hsp90 in Cancer.
    Wong DS; Jay DG
    Adv Cancer Res; 2016; 129():141-63. PubMed ID: 26916004
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Selective Inhibition of the Hsp90α Isoform.
    Mishra SJ; Khandelwal A; Banerjee M; Balch M; Peng S; Davis RE; Merfeld T; Munthali V; Deng J; Matts RL; Blagg BSJ
    Angew Chem Int Ed Engl; 2021 May; 60(19):10547-10551. PubMed ID: 33621416
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Heat shock protein 90 inhibitors as therapeutic agents.
    Gomez-Monterrey I; Sala M; Musella S; Campiglia P
    Recent Pat Anticancer Drug Discov; 2012 Sep; 7(3):313-36. PubMed ID: 22338602
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeting Heat-Shock Protein 90 (HSP90) as a Complementary Strategy to Immune Checkpoint Blockade for Cancer Therapy.
    Proia DA; Kaufmann GF
    Cancer Immunol Res; 2015 Jun; 3(6):583-9. PubMed ID: 25948551
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Old and New Approaches to Target the Hsp90 Chaperone.
    Sanchez J; Carter TR; Cohen MS; Blagg BSJ
    Curr Cancer Drug Targets; 2020; 20(4):253-270. PubMed ID: 31793427
    [TBL] [Abstract][Full Text] [Related]  

  • 35. HSP90 inhibitors: current development and potential in cancer therapy.
    Sidera K; Patsavoudi E
    Recent Pat Anticancer Drug Discov; 2014 Jan; 9(1):1-20. PubMed ID: 23312026
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeting chaperones in transformed systems--a focus on Hsp90 and cancer.
    Chiosis G
    Expert Opin Ther Targets; 2006 Feb; 10(1):37-50. PubMed ID: 16441227
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Right Tool for the Job: An Overview of Hsp90 Inhibitors.
    Koren J; Blagg BSJ
    Adv Exp Med Biol; 2020; 1243():135-146. PubMed ID: 32297216
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Heat shock proteins: new target in cytoprotective and tumor therapy].
    Bao XQ; Liu GT
    Yao Xue Xue Bao; 2008 Mar; 43(3):234-40. PubMed ID: 18630257
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Heat-shock protein 90 (Hsp90) as anticancer target for drug discovery: an ample computational perspective.
    Kumalo HM; Bhakat S; Soliman ME
    Chem Biol Drug Des; 2015 Nov; 86(5):1131-60. PubMed ID: 25958815
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nanoparticle approaches to combating drug resistance.
    Moon JH; Moxley JW; Zhang P; Cui H
    Future Med Chem; 2015 Aug; 7(12):1503-10. PubMed ID: 26334205
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.